FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis

OBJECTIVE: Fibroblast growth factor 21 (FGF21) shows great potential for the treatment of obesity and type 2 diabetes, as its long-acting analogue reduces body weight and improves lipid profiles of participants in clinical studies; however, the intracellular mechanisms mediating these effects are po...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Metab
Main Authors: Mottillo, Emilio P., Desjardins, Eric M., Fritzen, Andreas M., Zou, Vito Z., Crane, Justin D., Yabut, Julian M., Kiens, Bente, Erion, Derek M., Lanba, Adhiraj, Granneman, James G., Talukdar, Saswata, Steinberg, Gregory R.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5444097/
https://ncbi.nlm.nih.gov/pubmed/28580278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2017.04.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados